Phage Therapy Market Report with Forecast 2026 to 2035
Share With :
Global Phage Therapy Market is expected to grow at an 21.60% CAGR during the forecast period for 2026 to 2035.
Phage Therapy Market Size, Share & Trends Analysis Report By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Route of Administration (Oral, Topical, Rectal Route, Intravenous Route), by Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, Other Bacteria), by Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, Other Disease Indications), By Development Stage, By Product Type, By Target Indication, By Target Pathogen, Region And Segment Forecasts, 2026 to 2035.
Key Industry Insights & Findings from the Report:
Phage therapy industry is experiencing huge research and development activities to develop products for different diseases and applications.The global phage therapy market is under development with no FDA-approved products. In the current scenario, natural phage-based products and compassionate phage therapy (CPT) are available in the market, which comprises current market revenue. Players such as Microgen (Russia), Duopharm (Germany), SES DERMA (Peru), BIOMED PERM NPO (Russia), and Phage Therapy Center are offering treatment for patients with chronic infectious diseases. However, the global phage therapy market has a tremendous opportunity to grow during the forecast period. By region, Europe dominates the market with a share of 57.0% of the global phage therapy market. Russia and Germany are the key markets holding the majority of the market for phage therapy in the region.
The market has reputed players across the globe with massive investment in clinical trials/ R&D activities. Clinical trial/product development companies in the market form strategic alliances with key pharmaceutical vendors to seek investment and tap potential markets in upcoming forecast years. Strategic alliances with contract manufacturers, the scientific community, and policymakers will enhance the development of phage therapy for clinical trials companies. The rapid increase in investment in the phage industry has been seen in recent years due to significant market opportunities in upcoming years.
The global phage therapy market is segmented on the basis of Distribution Channel, Route of Administration, Targeted Bacteria, Disease Indication and region. As per the Distribution Channel, the market is categorized into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By Route of Administration, the market is divided into Oral, Topical, Rectal Route, and Intravenous Route. According to the Targeted Bacteria, the market is segmented into Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella, and Other Bacteria. The Disease Indication segment comprises Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, and Other Disease Indications. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and the Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 21.60% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026 to 2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Distribution Channel, By Route of Administration, By Target Pathogen, By Target Indication, By development stage, By Product Type, |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia; |
| Competitive Landscape | Armata Pharmaceuticals, Inc., BiomX (MBcure Ltd.), Eligo Bioscience, Intralytix, Inc., iNtODEWorld, Locus Biosciences, MicroPhage, Inc., TechnoPhage, Microgen Russia, Aumed, Aziya immunopreparat LLC, Sensei Biotherapeutics, Eliava BioPreparations, Nextbiotics, PhagePro, Nexabiome, Other Prominent Players |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.